About Hannah Sore

A medicinal chemist and entrepreneur, I am the CEO and co-founder of PharmEnable: a drug discovery company that develops the next generation of small molecule drugs using a combination of medicinal chemistry and a proprietary AI platform. A spinout from research at Cambridge University and part of the Cambridge Cluster (UK), PharmEnable raised £1.8m in seed financing in 2020 to develop our early stage drug discovery program.

Prior to PharmEnable, my experience within the life sciences and drug discovery sector includes Millennium Pharmaceuticals, Astex Therapeutics and the University of Cambridge, plus 10 years of consulting and business experience across healthcare sectors at Frost & Sullivan and HFS Scientific Ltd.